Results 11 to 20 of about 23,474 (264)

Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma [PDF]

Journal for ImmunoTherapy of Cancer, 2017
Background Immunotherapy plays a key role in the treatment of metastatic melanoma. Patients with autoimmune conditions and/or on immunosuppressive therapy due to orthotropic transplants, however, are systematically excluded from clinical trials ...
Gustavo Schvartsman, Kristen Perez, Jill E. Flynn, Jeffrey N. Myers, Hussein Tawbi   +4 more
doaj   +2 more sources

Inflammatory Colitis after Treatment of Melanoma with Talimogene Laherparepvec (T-VEC) [PDF]

Journal of Immunotherapy and Precision Oncology, 2018
Talimogene laherparepvec (T-VEC) is an intralesional oncolytic viral therapy for the treatment of recurrent, unresectable cutaneous, subcutaneous, and nodal melanoma.
Jennifer Gardner, Teresa Hyun, Gideon Steinbach, John Thompson   +3 more
doaj   +3 more sources

Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-negative breast cancer [PDF]

npj Breast Cancer
Talimogene laherparepvec (T-VEC) is an oncolytic virus that is hypothesized to enhance responses to systemic therapy. This Phase 1b trial evaluated the safety and efficacy of intratumoral T-VEC plus chemotherapy (CT) or endocrine therapy (ET) for ...
Laura A. Huppert, Amelia S. Gliwa, Madeline Tait, Laura Quintal, Stephanie Starzinski, Alexander Cheung, Mark Moasser, Melanie Majure, Michelle Melisko, Pamela Munster, Hope S. Rugo, Michael Campbell, Lawrence Fong, A. Jo Chien   +13 more
doaj   +2 more sources

Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review. [PDF]

Curr Oncol Rep
Abstract Purpose of review As the incidence of cutaneous melanoma continues to rise worldwide, its heterogeneous presentation proves challenging for managing and preventing relapse. Recent findings While surgery remains a mainstay in staging and treatment of locoregional ...
Kalsi S, Galenkamp AL, Singh R, Khosla AA, McGranaghan P, Cintolo-Gonzalez J.   +5 more
europepmc   +3 more sources

Real-World Experience of Talimogene Laherparepvec (T-VEC) in Old and Oldest-Old Patients with Melanoma: A Retrospective Single Center Study [PDF]

Cancer Management and Research, 2021
Johannes Kleemann, Manuel Jäger, Eva Valesky, Stefan Kippenberger, Roland Kaufmann, Markus Meissner Department of Dermatology, Venerology and Allergology, University Hospital, Goethe University, Frankfurt am Main, GermanyCorrespondence: Johannes ...
Kleemann J, Jäger M, Valesky E, Kippenberger S, Kaufmann R, Meissner M   +5 more
doaj   +2 more sources

Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma. [PDF]

Am J Clin Dermatol, 2017
Many mammalian viruses have properties that can be commandeered for the treatment of cancer. These characteristics include preferential infection and replication in tumor cells, the initiation of tumor cell lysis, and the induction of innate and adaptive anti-tumor immunity. Furthermore, viruses can be genetically engineered to reduce pathogenicity and
Bommareddy PK, Patel A, Hossain S, Kaufman HL.   +3 more
europepmc   +3 more sources

Talimogene Laherparepvec treatment for mucosal melanoma with metastatic lymph node metastasis: case report [PDF]

Frontiers in Oncology
Mucosal melanoma is a rare and aggressive subtype of melanoma, accounting for approximately 1% of all melanoma cases. Of those, only 4% occur primarily in the vagina.
Arnar B. Ingason, Venkatesa P. Muruganandam, Ikechukwu Chidobem, Jessica Cintolo-Gonzalez, Hibba tul Rehman   +4 more
doaj   +2 more sources

Enhanced Antitumor Activity and Induction of Immunogenic Cell Death in NUT Carcinoma Cells by Combining Oncolytic Viruses with the Dual Inhibitor NEO2734 [PDF]

Viruses
NUT carcinoma (NC) is a rare exceptionally aggressive malignancy, defined by NUTM1 gene translocations, most commonly generating a BRD4::NUTM1 fusion that results in a poor prognosis and limited therapeutic options. Oncolytic virotherapy has emerged as a
Fiona D. Nitschke, Julia Beil, Irina Smirnow, Andrea Schenk, Mary E. Carter, Ulrich M. Lauer, Linus D. Kloker   +6 more
doaj   +2 more sources

Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO) [PDF]

Nature Communications
This single-arm, phase II, preoperative window-of-opportunity trial (ClinicalTrials.gov Identifier: NCT03802604) investigated the efficacy and safety of talimogene laherparepvec (T-VEC), an oncolytic virus, with atezolizumab, an anti–PD-L1 antibody, in ...
Tomás Pascual, Maria Vidal, Juan M. Cejalvo, Estela Vega, Esther Sanfeliu, Guillermo Villacampa, Sergi Ganau, Ana María Julve Parreño, Esther Zamora, Ignacio Miranda, Ana Delgado, Begoña Bermejo, Elia Seguí, Fara Brasó-Maristanty, Luis de la Cruz-Merino, Manel Juan, Patricia Galván, Xavier Gonzàlez-Farré, Samyukta Chillara, Patricia Villagrasa, Adam D. Pfefferle, Constandina E. O’Connell, Juan M. Ferrero-Cafiero, Mafalda Oliveira, Charles M. Perou, Aleix Prat   +25 more
doaj   +2 more sources

Real-world outcomes of talimogene laherparepvec as salvage therapy for advanced melanoma [PDF]

Journal for ImmunoTherapy of Cancer
Background Talimogene laherparepvec (T-VEC) is an oncolytic herpes simplex virus therapy approved for treatment of unresectable and metastatic melanoma. However, real-world use often occurs in heavily pretreated patients, where evidence of effectiveness ...
Shailender Bhatia, Paul T Nghiem, George Ansstas, Song Y Park, Coley Doolittle-Amieva, Evan T Hall, Melissa M Yamada, Smitha Chandrasekhar, Ted A Gooley, Rita E Chen, David Y Chen   +10 more
doaj   +2 more sources